PCRX · Pacira BioSciences, Inc.
$25.88
+1.28% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$1B
Trailing P/E
203.6
Forward P/E
7.3
Dividend yield
—
Beta
0.27
Avg volume
1M
Employees
1K
2D change
—
5D change
2.08%
10D change
3.36%
30D change
4.87%
60D change
14.00%
MTD change
5.75%
YTD change
2.28%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PCRX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-01
Latest call per bank · past 12 months
RBC Capital
Sector Perform$24.00
-7.3% vs priceBarclays
Equal-Weight$25.00
-3.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-01 | HC Wainwright & Co. | Reiterates | Buy | $38.00 |
| 2026-05-01 | RBC Capital | Maintains | Sector Perform | $22.00 → $24.00 |
| 2026-05-01 | Needham | Maintains | Buy | $30.00 → $32.00 |
| 2026-03-26 | Barclays | Maintains | Equal-Weight | $27.00 → $25.00 |
| 2026-01-09 | HC Wainwright & Co. | Reiterates | Buy | $38.00 |
| 2026-01-09 | Needham | Maintains | Buy | $30.00 |
| 2025-12-09 | Barclays | Initiates | Equal-Weight | $0.00 → $27.00 |
| 2025-11-07 | Truist Securities | Maintains | Buy | $30.00 → $28.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 70 — overbought territory; the recent run-up may be due for a pause.
- Price vs 50-day MA: Trading 11.1% above the 50-day MA ($24.14).
- Price vs 200-day MA: Trading 14.5% above the 200-day MA ($23.41).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.06) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($27.22).
PCRX Price Chart
Loading chart for PCRX…
Fundamentals
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.